Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed

Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed

By

Alprazolam was found to be the most commonly misused benzodiazepine.

Clinicians on Sufentanil Sublingual Tablet Safety Study

Clinicians on Sufentanil Sublingual Tablet Safety Study

By

The pooled analysis (N=804) evaluated clinical studies of sufentanil sublingual tablet (SST) at 30mcg dose equivalents over ≤72 hours for moderate-to-severe acute pain management in both postoperative and emergency room patients.

FDA Approves Two New Strengths of Apadaz for Pain Management

FDA Approves Two New Strengths of Apadaz for Pain Management

By

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Additional Naloxone Formulation Submitted to FDA for Review

Additional Naloxone Formulation Submitted to FDA for Review

By

Currently, naloxone is supplied in ampules and vials for IV, IM or SC administration, in a prefilled auto-injector, and as a nasal spray.

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

By

Brixadi utilizes FluidCrystal Injection Depot Technology; once in contact with fluids in the tissue, the solution turns into a nanostructured liquid-crystalline gel allowing for slow release of buprenorphine at a steady rate over 1 week or 1 month.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-Newsletters